RMC No. 116-2022 updates the VAT-exempt medicines list under CREATE, adding certain chronic disease medicines and deleting some COVID-19 medicines.
Pharmacies, hospitals, clinics, distributors, importers, and accounting teams handling medicines must immediately check whether their products remain VAT-exempt, newly qualify for VAT exemption, or have been removed from the VAT-exempt list. RMC No. 116-2022 confirms updates to the List of VAT-Exempt Medicines under Republic Act No. 11534, otherwise known as the CREATE Act, based on the July 11, 2022 endorsement of the Food and Drug Administration. The practical consequence is direct: certain medicines for hypertension, diabetes, high cholesterol, kidney diseases, mental illness, and cancer may now be treated as VAT-exempt if included in the updated list, while certain medicines previously listed for COVID-19 treatment have been deleted and should no longer be treated as VAT-exempt merely on the basis of the prior list.
What RMC No. 116-2022 Changed
RMC No. 116-2022 published the July 11, 2022 letter from FDA OIC-Director General Oscar G. Gutierrez, Jr. endorsing updates to the List of VAT-Exempt Medicines under the CREATE Act. The update affects the tax treatment of covered medicines because the VAT exemption under the CREATE Act is tied to the updated list published by the FDA. For affected businesses, this is not merely a technical announcement. It changes how certain medicines should be treated for VAT invoicing, pricing, accounting, point-of-sale configuration, tax reporting, and internal compliance review.
The updated list includes certain medicines prescribed for hypertension, diabetes, high cholesterol, kidney diseases, mental illness, and cancer. At the same time, it deletes certain medicines prescribed for COVID-19 treatment that had previously been included in the published list. This means taxpayers cannot safely rely on an older VAT-exempt medicines list without confirming whether the particular medicine remains included after the FDA update endorsed in RMC No. 116-2022.
Who Is Most Affected by the Updated VAT-Exempt Medicines List
The taxpayers most affected are businesses in the pharmaceutical and healthcare supply chain. This includes drugstores, hospital pharmacies, clinics dispensing medicines, pharmaceutical wholesalers, medicine importers, distributors, and retailers selling products that fall within the covered disease categories. Accounting teams of hospitals and pharmacies should treat this issuance as a VAT classification update because the same product category may not always mean the same VAT result unless the medicine is actually included in the applicable VAT-exempt medicines list.
CFOs, corporate accountants, and tax managers should pay particular attention if the business sells medicines for hypertension, diabetes, high cholesterol, kidney diseases, mental illness, cancer, or COVID-19 treatment. These are the search terms and operational categories most likely to trigger VAT treatment questions under RMC No. 116-2022. For example, a company may need to determine whether a medicine for diabetes is now covered by the VAT exemption, while also checking whether a COVID-19 medicine previously treated as VAT-exempt has been deleted from the list.
Effectivity of the VAT Exemption
RMC No. 116-2022 reiterates the rule clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021: the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act takes effect on the date of publication by the FDA of the updates to the list. This is a critical timing rule. The VAT exemption does not apply based solely on the date a business learns about the update, the date its accounting system is adjusted, or the date the BIR circular is read by the taxpayer. The operative reference stated in the circular is the date of publication by the FDA of the updates to the List of VAT-Exempt Medicines.
For compliance purposes, businesses should review sales and purchases around the relevant publication date and determine whether VAT was correctly imposed, excluded, booked, and reported. If a medicine became VAT-exempt upon FDA publication, invoices and receipts issued after effectivity should reflect the correct VAT treatment. Conversely, if a COVID-19 treatment medicine was deleted from the published list, businesses should avoid continuing VAT-exempt treatment after the applicable update unless another valid basis applies.
Key Compliance Requirements for Pharmacies, Hospitals, and Medicine Sellers
The first compliance task is product-level matching. A business should compare its medicine master list, inventory records, sales database, and tax codes against the updated FDA-published list referenced in RMC No. 116-2022. The review should not be limited to broad therapeutic categories. The circular refers to certain medicines, not all medicines, prescribed for hypertension, diabetes, high cholesterol, kidney diseases, mental illness, and cancer. Therefore, the safer approach is to confirm the specific product included in the FDA update before applying VAT-exempt treatment.
The second task is to update VAT coding in the company’s invoicing, accounting, and point-of-sale systems. For covered products, the system should be able to distinguish VAT-exempt medicines from taxable goods. This is especially important for pharmacies and hospitals that sell both VAT-exempt and VATable items in the same transaction. Misclassification can distort output VAT reporting, pricing, inventory valuation, and reconciliation of tax returns.
The third task is to review COVID-19 treatment medicines that were previously treated as VAT-exempt. RMC No. 116-2022 expressly states that certain medicines prescribed for COVID-19 treatment previously included in the published list were deleted. This deletion is operationally important because front-line pharmacy and accounting personnel may continue using old tax codes unless the compliance team issues a clear update. Businesses should identify the affected COVID-19 medicines, revise internal tax matrices, and document the basis for any change in tax treatment.
Penalties and Risk of Non-Compliance
RMC No. 116-2022 does not state a special penalty unique to this update. However, the absence of a special penalty does not make the issue low-risk. Incorrect VAT treatment can create tax exposure during BIR audit, especially where a business treats a taxable medicine as VAT-exempt after deletion from the list, or where records do not support why VAT was not imposed on a sale. For finance teams, the key risk is not only the amount of VAT involved but also the documentation trail showing how the business determined the correct treatment.
Businesses should also consider customer-facing risks. If VAT is charged on a medicine that should be VAT-exempt, the issue may create refund, billing, or customer complaint concerns. If VAT is not charged on a medicine that is no longer covered, the seller may later face difficulty recovering the tax from customers after the sale. This is why the RMC No. 116-2022 VAT-exempt medicines update should be handled as both a tax compliance matter and an operational pricing issue.
Practical Steps Businesses Should Take Now
Companies should begin with a written internal review of all medicines sold or purchased under the affected categories: hypertension medicines, diabetes medicines, high cholesterol medicines, kidney disease medicines, mental illness medicines, cancer medicines, and COVID-19 treatment medicines. The review should identify which products are newly covered, which remain covered, and which have been deleted from the VAT-exempt medicines list.
After the product review, the business should update its accounting system, billing templates, point-of-sale tax codes, and sales personnel guidance. A short internal advisory should be issued to pharmacy, accounting, procurement, and sales teams explaining that VAT exemption depends on inclusion in the updated FDA-published list and that certain COVID-19 medicines previously included have been deleted. Companies should also preserve a copy of the internal review and approval trail so that the basis for VAT treatment can be explained during audit.
For businesses with multiple branches, the compliance update should be implemented uniformly. Branch-level personnel should not independently decide whether a medicine is VAT-exempt based only on product category or prior practice. A central tax or finance team should maintain the official product tax matrix and confirm the effectivity date based on the FDA publication rule referenced in RMC No. 116-2022 and RMC No. 99-2021.
Why RMC No. 116-2022 Matters for Tax Planning and Pricing
VAT exemption affects pricing, margins, customer billing, and tax return preparation. For pharmacies and healthcare providers, a product’s inclusion in or deletion from the VAT-exempt medicines list can change how the final price is computed and how the transaction is reported. For distributors and importers, the same update may affect commercial discussions with buyers that expect correct VAT treatment on covered medicines.
RMC No. 116-2022 is therefore important not only for tax departments but also for business owners and CFOs responsible for pricing strategy and compliance controls. The key phrase for accountants is simple: RMC No. 116-2022 updated the VAT-exempt medicines list under the CREATE Act, including certain medicines for hypertension, diabetes, high cholesterol, kidney diseases, mental illness, and cancer, while deleting certain COVID-19 treatment medicines from the prior list.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists pharmacies, healthcare companies, distributors, importers, hospitals, and corporate taxpayers in reviewing BIR issuances, updating VAT compliance procedures, and preparing defensible tax documentation. Our team can help determine how RMC No. 116-2022 affects your product list, invoicing system, branch operations, and tax reporting position.
For businesses that need urgent assistance with VAT-exempt medicines, CREATE Act compliance, BIR audit readiness, or tax classification of healthcare products, consult Ablola, Saribong & Gueco through MakatiLawFirm.com.